5.6.2023
The annual meeting of the European Society for Radiotherapy and Oncology (ESTRO) took place in Vienna from 12 to 15 May, gathering over 6000 professionals. More than 2500 abstracts on radiotherapy-related research projects were spread among 197 sessions. May was also cancer research month and international women’s health month. Since…
Articles
11.4.2023
More than half a million people are diagnosed each year with esophageal cancer. It is the 8th most common cancer type and places sixth regarding mortality[1]. Several factors influence the treatment decision with this cancer diagnosis, like the stage of the disease, the tumor site, the pathological type, and the…
23.3.2023
HELSINKI, Finland - March 23, 2023 MVision AI raises 5.4M€ to make same-day cancer treatment the new standard MVision AI is the first cloud-based AI-powered radiotherapy planning solution for treating cancer. MVision uses artificial intelligence to automate cancer treatments with its unique automatic segmentation tool. The next-generation technology speeds up…
Press Releases
20.2.2023
One of the main characteristics of humans, compared to most other living creatures, is the ability of making tools. Progress has been linked to discoveries and the development of new devices. People have always tried to enhance their capabilities, and our days are not different. But how do we perceive…
16.1.2023
The generation of synthetic images has greatly advanced in recent years due to the progress of artificial intelligence. Some of the applications have recently been widely popularized in media, especially art and fashion generation and videos/photos creation of realistic-looking human faces¹. The image-to-image translation is a special case of synthetic…
9.1.2023
S Warren, N Richmond MVision AI software has been under evaluation at NCCC (Newcastle upon Tyne Hospitals NHS Foundation Trust) since 28 February 2022* in order to: 1. compare AI contour quality and consistency with manual contouring; 2. estimate potential improvements in efficiency; 3. identify opportunities to improve clinical workflow.…
29.7.2022
Background Glioblastoma multiforme represents approximately half of the cases of central nervous system malignant tumors. The median age at diagnosis is 64 years, and the incidence was reported to be approximately 3 cases in 100 000 people. Genetic conditions, such as Li Fraumeni and Lynch Syndrome, are associated with a…
31.5.2022
Helsinki, 31st of May, 2022 - MVision AI announces that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for guideline-based, AI-powered software for automatic segmentation for radiotherapy. (more…)
News, Press Releases
24.2.2022
Machine learning has become vital to the modern world, turning data into real, actionable insights. In radiotherapy, there has been a continuous increase in patient-specific needs met with the help of artificial intelligence, from quality personalized treatment to medical imaging. In the machine learning field, there are two main types…
News
7.1.2022
According to the NHS, breast cancer is the most common type of cancer in the UK. Roughly 1 in 8 women are diagnosed with breast cancer during their lifetime. However, there is a good chance of recovery if the cancer is detected early. (NHS) The World Health Organization estimates that…
29.12.2021
2021 is an innovative and foundational year for MVision AI. We are proud of what we have accomplished so far and super excited about what is in store for us in the future. One feeling that stands out as we look back at 2021 is gratitude. We thank everyone who…
9.12.2021
Helsinki – December 9, 2021 – MVision AI, the leading software service provider of guideline-based AI segmentation, GBAIS™, for radiotherapy treatment planning, declares a new distribution partnership with Medron Medical Systems, Canada’s choice health equipment provider (subject to approval from Health Canada). (more…)
Subscribe to get information, latest news and other interesting offers about MVision AI
